Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$8.63 - $15.52 $31.7 Million - $57 Million
-3,670,870 Reduced 47.27%
4,095,069 $36.3 Million
Q2 2022

Aug 15, 2022

SELL
$8.59 - $20.77 $11.5 Million - $27.8 Million
-1,339,164 Reduced 14.71%
7,765,939 $98.2 Million
Q1 2022

May 16, 2022

BUY
$15.52 - $35.65 $779,290 - $1.79 Million
50,212 Added 0.55%
9,105,103 $174 Million
Q4 2021

Feb 14, 2022

BUY
$28.89 - $35.33 $3.71 Million - $4.54 Million
128,422 Added 1.44%
9,054,891 $318 Million
Q3 2021

Nov 15, 2021

BUY
$35.66 - $42.94 $73.7 Million - $88.7 Million
2,066,652 Added 30.13%
8,926,469 $326 Million
Q2 2021

Aug 16, 2021

BUY
$23.7 - $39.27 $27.5 Million - $45.5 Million
1,159,253 Added 20.34%
6,859,817 $262 Million
Q1 2021

May 14, 2021

BUY
$27.01 - $36.8 $30.5 Million - $41.5 Million
1,127,862 Added 24.67%
5,700,564 $161 Million
Q4 2020

Feb 12, 2021

BUY
$27.51 - $34.36 $1.8 Million - $2.24 Million
65,260 Added 1.45%
4,572,702 $146 Million
Q3 2020

Nov 13, 2020

BUY
$25.8 - $34.61 $8.77 Million - $11.8 Million
339,879 Added 8.16%
4,507,442 $145 Million
Q2 2020

Aug 14, 2020

BUY
$17.65 - $28.05 $19.8 Million - $31.5 Million
1,122,483 Added 36.86%
4,167,563 $115 Million
Q1 2020

May 15, 2020

BUY
$15.19 - $29.51 $17.1 Million - $33.2 Million
1,126,259 Added 58.7%
3,045,080 $54.4 Million
Q4 2019

Feb 18, 2020

BUY
$17.17 - $25.95 $11.4 Million - $17.2 Million
662,934 Added 52.79%
1,918,821 $48.1 Million
Q3 2019

Nov 14, 2019

BUY
$17.84 - $22.69 $4.45 Million - $5.65 Million
249,180 Added 24.75%
1,255,887 $22.4 Million
Q2 2019

Aug 14, 2019

BUY
$22.0 - $31.78 $9.2 Million - $13.3 Million
418,219 Added 71.07%
1,006,707 $22.1 Million
Q1 2019

May 15, 2019

BUY
$21.27 - $30.58 $12.5 Million - $18 Million
588,488 New
588,488 $235 Million

Others Institutions Holding HCM

About HUTCHMED (China) Ltd


  • Ticker HCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 172,955,008
  • Market Cap $3.11B
  • Description
  • HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...
More about HCM
Track This Portfolio

Track Capital International Investors Portfolio

Follow Capital International Investors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital International Investors with notifications on news.